Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
September 09 2009 - 6:30AM
PR Newswire (US)
THE WOODLANDS, Texas, Sept. 9 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX), a biopharmaceutical company
focused on discovering and developing breakthrough treatments for
human disease, announced today that Arthur T. Sands, M.D., Ph.D.,
Lexicon's president and chief executive officer, will present at
the Morgan Stanley Global Healthcare Unplugged Conference at the
Grand Hyatt hotel in New York, New York on Tuesday, September 15,
2009 at 1:35 p.m. Eastern Time. About Lexicon Lexicon is a
biopharmaceutical company focused on discovering and developing
breakthrough treatments for human disease. Lexicon currently has
five drug candidates in development for autoimmune disease,
carcinoid syndrome, diabetes, glaucoma and irritable bowel
syndrome, all of which were discovered by the company's research
team. The company has used its proprietary gene knockout technology
to identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about Lexicon and
its programs, please visit http://www.lexpharma.com/. Safe Harbor
Statement This press release contains "forward-looking statements,"
including statements relating to Lexicon's growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's ability
to successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Risk Factors"
in Lexicon's annual report on Form 10-K for the year ended December
31, 2008, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: Lexicon Pharmaceuticals,
Inc. CONTACT: Jason Ray, Manager, Corporate Communications and
Investor Relations of Lexicon Pharmaceuticals, +1-281-863-3225, Web
Site: http://www.lexpharma.com/
Copyright